Evidence map›Paper›PMID 34150810›Full record

ArticleFrontiers in medicine2021

Case Report: Lipoprotein Glomerulopathy Complicated by Atypical Hemolytic Uremic Syndrome.

Lara Kollbrunner, Patricia Hirt-Minkowski, Javier Sanz, Elena Bresin, Thomas J Neuhaus, Helmut Hopfer, Andreas W Jehle

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Lipoprotein Glomerulopathy, First Case Report from Canada.International journal of nephrology and renovascular disease · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Lara KollbrunnerDepartment of Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland.
Patricia Hirt-MinkowskiTransplantation Immunology and Nephrology, University Hospital Basel, Basel, Switzerland.
Javier SanzDivision of Human Genetics, University Hospital of Bern, Bern, Switzerland.
Elena BresinIstituto di Ricerche Farmacologiche Mario Negri Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Bergamo, Italy.
Thomas J NeuhausDepartment of Pediatrics, Lucerne Children's Hospital, Cantonal Hospital Lucerne, Lucerne, Switzerland.
Helmut HopferInstitute for Pathology, University Hospital Basel, Basel, Switzerland.
Andreas W JehleDepartment of Internal Medicine, Hirslanden Klinik St. Anna, Lucerne, Switzerland.
University Hospital of Basel · CHHirslanden Klinik St. Anna · CHIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversity Hospital of Bern · CHUniversity of Teacher Education Lucerne · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lipoprotein glomerulopathy (LPG) is a rare inherited disease caused by mutations in the APOE gene, encoding apolipoprotein E (apoE). Atypical hemolytic uremic syndrome (aHUS) is a thrombotic microangiopathy (TMA) characterized by overactivation of the alternative complement pathway. Here we report the case of a 21-year-old man with LPG who developed aHUS. A functional complement assay demonstrated an overactivation of the complement system. Complementary genetic analysis revealed a homozygous aHUS risk allele for complement factor-H related 1 (CFHR1), CFHR1

Indexed as

apolipoprotein Eatypical hemolytic uremic syndromecase reportcomplement factor-H related 1lipoprotein glomerulopathynephrotic syndromethrombotic microangiopathy

Identifiers

PMID34150810
PMCPMC8206272
OpenAlexW3171574420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.